Lineage Cell Therapeutics (NYSE: LCTX) reported Q1 EPS of ($0.01), $0.02 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $391 thousand versus the consensus estimate of $350 thousand.

For earnings history and earnings-related data on Lineage Cell Therapeutics (LCTX) click here.